| Cat. No. | Product name | CAS No. |
| DCS-114 |
Embelin
>98%,Standard References |
550-24-3 |
| DCL-047 |
Sulforaphane
>98%,Standard References |
4478-93-7 |
| DCS-091 |
Cephalomannine
>98%,Standard References |
71610-00-9 |
| DCC-002 |
Vinblastine
>98%,Standard References |
865-21-4 |
| DCQ-004 |
4'-Demethylepipodophyllotoxin
>98%,Standard References |
6559-91-7 |
| DCJ-030 |
Galanthamine
>98%,Standard References |
357-70-0 |
| DCW-011 |
Evocarpine
>98%,Standard References |
15266-38-3 |
| DCL-027 |
Lipoic acid
Featured
Lipoic acid is a selective, small molecule large-conductance Ca(2+)-activated K(+) channel (BKCa, KCa1.1, MaxiK) positive modulator with EC50 of 11 uM. Lipoic acid shows a favorable selectivity profile on Nav, Cav, SK, and IK channels. Lipoic acid causes distinct activation from a concentration of 0.3 and 10 µM Lipoic acid left-shifted the voltage activation curve by 60 mV. Lipoic acid reduces spontaneous phasic contractions in guinea pig urinary bladder strips at 1 uM, while having only a modest effect on contractions evoked by electrical field stimulation (EFS) and no effect on high K+-induced contractions. |
62-46-4 |
| DC22287 |
Atractylenolide I
Featured
Atractylenolide I is a sesquiterpene derived from the rhizome of Atractylodes macrocephala, possesses diverse bioactivities, such as neuroprotective, anti-allergic, anti-inflammatory and anticancer properties. Atractylenolide I reduces protein levels of phosphorylated JAK2 and STAT3 in A375 cells, and acts as a TLR4-antagonizing agent. |
73069-13-3 |
| DC23034 |
Isochlorogenic acid C
Featured
4,5-Dicaffeoylquinic acid ( Isochlorogenic acid C) possesses potent hepatoprotective and anti-HBV effects.IC50 value:Target: Anti-hepatitis natural produce.In vitro: To study anti-hepatitis effect of isochlorogenic acid C, anti-apoptotic and anti-injury properties of test compound were evaluated. The results showed that test compound at concentrations of 10 to 100 μg/ml significantly reduced the caspase-3 and transformed growth factor β1 (TGFβ1) levels of the D-GalN-challenged hepatocytes. Also, test compound improved markedly cell viability of the D-GalN-injured hepatocytes and produced a maximum protection rate of 47.28% at a concentration of 100 μg/ml. Furthermore, test compound significantly inhibited productions of HBsAg and HBeAg. Its maximum inhibitory rates on the HBsAg and HBeAg expressions were 86.93 and 59.79%, respectively. In addition, test compound significantly induced the HO-1 expression of HepG2.2.15 cells [1]. In vivo: |
57378-72-0 |
| DCF-029 |
Columbamine
>98%,Standard References |
3621-36-1 |
| DCG-045 |
Nardosinone
>98%,Standard References |
23720-80-1 |
| DCL-036 |
Glucosamine sulfate
>98%,Standard References |
14999-43-0 |
| DCZ-276 |
5-Hydroxy-1-tetralone
>98%,Standard References |
28315-93-7 |
| DCZ-277 |
Methyl 4-hydroxycinnamate
>98%,Standard References |
19367-38-5 |
| DCZ-104 |
4-HYDROXY-3-METHOXYCINNAMALDEHYDE
>98%,Standard References |
458-36-6 |
| DCL-018 |
2-Methoxycinnamic acid
>98%,Standard References |
6099-03-2 |
| DCY-044 |
3-Hydroxy-4-methoxycinnamic acid
>98%,Standard References |
537-73-5 |
| DCJ-059 |
Inosine
>98%,Standard References |
58-63-9 |
| DCH-024 |
cis-Anethol
>98%,Standard References |
104-46-1 |
| DCF-022 |
4-(4-Hydroxyphenyl)-2-butanone
>98%,Standard References |
5471-51-2 |
| DCY-147 |
Isoeugenol
>98%,Standard References |
97-54-1 |
